TEHRAN, July 15 — The International Atomic Energy Agency’s latest assessments continue to place Iran’s nuclear program at the centre of a widening international confrontation, with enrichment levels that experts describe as dangerously close to weapons-grade capability. According to IAEA reports from 2023, Iran has been enriching uranium to 60% purity — a significant step from the 3.67% limit established under the Joint Comprehensive Plan of Action, the 2015 nuclear deal.
The agency has estimated that Iran has stockpiled approximately 4.5 kilograms of enriched uranium at that level as of May 2023. The 90% threshold is widely considered the benchmark for weapons-grade material.
Iran maintains that its nuclear activities are for peaceful purposes. The United States and Israel, however, view the program as a direct threat to regional stability and non-proliferation efforts.
A deal undone
The JCPOA was signed in 2015 between Iran and world powers, placing strict limits on Iran’s enrichment capacity in exchange for sanctions relief. The United States withdrew from the agreement in 2018 under President Donald Trump, a move that set in motion Iran’s gradual abandonment of the deal’s restrictions. Since the withdrawal, Iran has breached multiple limits set by the accord.
The IAEA has documented enrichment levels rising steadily, with inspectors unable to fully verify the nature of Iran’s activities at several undeclared sites. The agency’s ability to monitor the program has been a recurring point of friction between Tehran and the international community.
The 2024 strikes — which some analysts believe were aimed at delaying or degrading nuclear facilities — remain unconfirmed in their specific targets. What is clear is that the underlying tensions have not subsided. The U.S. administration under President Trump has maintained a policy of maximum pressure, while Iran has continued to expand its enrichment capacity.
What the numbers suggest
For patients of international diplomacy watching this closely, the encouraging part is that the IAEA continues to maintain a presence and issue reports. The agency’s data provides a verifiable baseline. Early findings suggest that while Iran’s stockpile remains below weaponisation levels, the trajectory has been concerning for years.
Patients should understand that enrichment at 60% is not the same as having a weapon. It does, however, shorten the time needed to produce weapons-grade material significantly.
That distinction matters when assessing the risk of escalation. Israel has long viewed Iran’s nuclear ambitions as an existential threat. The U.S. has made clear it will not allow Iran to obtain a nuclear weapon.
Iran’s government has repeatedly stated it has no intention of building a bomb. The gap between these positions has not narrowed.
Looking ahead
What to watch next will depend on the IAEA’s ability to conduct inspections and the political will in Tehran and Washington to return to some form of negotiated framework. The JCPOA as originally structured is no longer in effect, but elements of it remain a reference point for any future agreement. For now, the facts on the ground are these: Iran enriches at 60%, the IAEA monitors what it can, and the U.S. and Israel view the program as a threat that may require further action.
The encouraging part is that diplomacy has not been entirely abandoned, and the IAEA continues to provide the evidence base that policymakers need. Patients should talk to their elected representatives about the importance of sustained oversight.
Consult your doctor — or in this case, your government — for the latest guidance on what these developments mean for regional security.
